Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Clinical trial NCT07372079 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07372079
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Neoadjuvant Therapy Immune Checkpoint Inhibitors QL1706

Start date: 2026-04-05
Primary completion: 2028-12-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.